pdgf-r-alpha-protein-mouse-528a-a-hek293-his

By Targets:	Akt (1) AMPK (1) Apoptosis (31) Aurora Kinase (3) Autophagy (34) Bcr-Abl (17) c-Fms (10) c-Kit (56) c-Met/HGFR (4) c-Myc (1) Casein Kinase (1) CDK (2) Checkpoint Kinase (Chk) (1) Discoidin Domain Receptor (1) DNA-PK (1) Drug Metabolite (11) EGFR (6) Ephrin Receptor (2) ERK (1) FAK (1) Ferroptosis (3) FGFR (44) FLT3 (23) Influenza Virus (1) IRE1 (3) Isotope-Labeled Compounds (9) JAK (1) MEK (1) Mitophagy (3) mTOR (2) PDGFR (125) PI3K (3) PROTACs (1) RAD51 (2) Raf (10) RET (15) SARS-CoV (4) Src (17) Tie (3) Tyrosinase (1) VEGFR (90)
By Research Areas:	Cancer (143) Cardiovascular Disease (8) Infection (3) Inflammation/Immunology (6) Neurological Disease (1)

Targets Recommended: 5 alpha Reductase IFNAR α-synuclein PGC-1α

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103032

Multi-kinase inhibitor 1	PDGFR c-Kit Bcr-Abl	Cancer
Multi-kinase inhibitor 1 is a potent multi-kinase inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of *PDGF-R, c-Kit* and Bcr-abl .

HY-112412

PDGFR Tyrosine Kinase Inhibitor III pdgf Receptor Tyrosine Kinase Inhibitor III	PDGFR	Neurological Disease
PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III), a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine Kinase Inhibitor III can be used for the research of amyotrophic lateral sclerosis .

HY-101042

AG-494 Tyrphostin AG 494	EGFR CDK	Cancer
AG-494 (Tyrphostin AG 494) is a potent and selective EGFR tyrosine kinase inhibitor (IC₅₀=0.7 μM). AG-494 inhibits the autophosphorylation of EGFR, ErbB2, HER1-2 and PDGF-R with IC₅₀s 1.1, 39, 45 and 6 μM, respectively. AG-494 blocks Cdk2 activation and inhibits EGF-dependent DNA synthesis .

HY-144653

PDGFR-IN-1	PDGFR Apoptosis	Cancer
PDGFR-IN-1 (compound 7m) is a potent and orally active *PDGFR* (platelet-derived growth factor receptor) inhibitor, with IC₅₀ values of 2.4 and 0.9 nM for PDGFRα and PDGFRβ, respectively. PDGFR-IN-1 displays robust antitumor effects and low toxicity, and can be used to study osteosarcoma .

HY-112337

VEGFR-2-IN-44	VEGFR PDGFR	Cancer
VEGFR-2-IN-44 (compound 4b) is a selective VEGF-R2 (Flk-1) inhibitor with an IC₅₀ value of 70 nM. VEGFR-2-IN-44 also inhibits PDGF-Rβ with an IC₅₀ of 920 nM .

HY-P0175

740 Y-P 125+ Cited Publications 740YpdgfR; pdgfR 740Y-P	PI3K Autophagy	Cancer
740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .

HY-111507

PDGFRα kinase inhibitor 1	PDGFR	Cancer
PDGFRα kinase inhibitor 1 is a highly selective type II PDGFRα kinase inhibitor with IC₅₀s of 132 nM and 6115 nM for PDGFRα and PDGFRβ, respectively .

HY-12050

CP-673451

5+ Cited Publications

PDGFR Cancer

CP-673451 is a potent and selective inhibitor of PDGFR with IC₅₀s of 10 and 1 nM for PDGFRα and PDGFRβ, respectively.

CP-673451 5+ Cited Publications	PDGFR	Cancer
CP-673451 is a potent and selective inhibitor of *PDGFR* with IC₅₀s of 10 and 1 nM for PDGFRα and PDGFRβ, respectively.

HY-108628

SU16f 1 Publications Verification	PDGFR	Cancer
SU16f is a potent and selective PDGFRβ inhibitor with IC₅₀s of 10 nM, 140 nM, 2.29 μM for PDGFRβ, PDGFR1, PDGFR2, respectively . Neutralization of PDGFRβ receptor by SU16f blocks the promoting role of GC-MSCs (gastric cancer-derived mesenchymal stem cells) conditioned medium in gastric cancer cell proliferation and migration .

HY-13493

AC710

PDGFR c-Kit FLT3 Cancer

AC710 is a potent PDGFR inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.
HY-13493A

AC710 Mesylate

PDGFR Cancer

AC710 Mesylate is a potent PDGFR inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.

AC710	PDGFR c-Kit FLT3	Cancer
AC710 is a potent *PDGFR* inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.

AC710 Mesylate	PDGFR	Cancer
AC710 Mesylate is a potent *PDGFR* inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.

HY-101957

AG 1295 2 Publications Verification	PDGFR	Cardiovascular Disease
AG 1295 is a selective platelet-derived growth factor receptor (PDGFR) tyrosine-kinase inhibitor. AG1295 abolishes autophosphorylation of the PDGFR whereas not affects the autophosphorylation of the EGF receptor .

HY-P99223

Tovetumab MEDI-575	PDGFR	Cancer
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) .

HY-145903

PDGFRα/FLT3-ITD-IN-2	PDGFR FLT3	Cancer
PDGFRα/FLT3-ITD-IN-2 (Compound 13d) is a potent inhibitor of PDGFRα/FLT3 with IC₅₀s of more than 20 and 1.654 μM, respectively. PDGFRα/FLT3-ITD-IN-2 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia .

HY-145904

PDGFRα/FLT3-ITD-IN-3	PDGFR FLT3	Cancer
PDGFRα/FLT3-ITD-IN-3 (Compound 18d) is a potent inhibitor of PDGFRα/FLT3 with IC₅₀s of 0.153 and 0.004 μM, respectively. PDGFRα/FLT3-ITD-IN-3 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia .

HY-145902

PDGFRα/FLT3-ITD-IN-1	PDGFR FLT3	Cancer
PDGFRα/FLT3-ITD-IN-1 (Compound 12d) is a potent inhibitor of PDGFRα/FLT3 with IC₅₀s of more than 0.036 and 0.003 μM, respectively. PDGFRα/FLT3-ITD-IN-1 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia .

HY-13049

Cediranib maleate 5+ Cited Publications AZD-2171 maleate	VEGFR Autophagy PDGFR	Cancer
Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC₅₀s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.

HY-10205

Cediranib 5+ Cited Publications AZD2171	VEGFR Autophagy PDGFR	Cancer
Cediranib (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC₅₀s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.

HY-10873

N-Desethyl Sunitinib 5 Publications Verification SU-12662	Drug Metabolite	Cancer
N-Desethyl Sunitinib (SU-12662) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor with K_i values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively .

HY-138813

N-Desethyl Sunitinib hydrochloride 5 Publications Verification SU-12662 hydrochloride	Drug Metabolite	Cancer
N-Desethyl Sunitinib (SU-12662) (hydrochloride) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor with K_i values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively .

HY-109190

Seralutinib 1 Publications Verification GB002; PK10571	PDGFR c-Fms c-Kit	Cardiovascular Disease
Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KIT with IC₅₀s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension .

HY-10330

Toceranib SU11654; PHA 291639E	PDGFR VEGFR c-Kit	Cancer
Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits *PDGFR, VEGFR, and Kit* with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors .

HY-10330A

Toceranib phosphate SU11654 phosphate; PHA 291639E phosphate	PDGFR VEGFR c-Kit	Cancer
Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits *PDGFR, VEGFR, and Kit* with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors .

HY-160053

Gint4.T aptamer sodium	PDGFR	Cancer
Gint4.T aptamer sodium is a nuclease-resistant RNA aptamer-based antagonist targeting platelet-derived growth factor receptor beta (PDGFRβ) (Kd: 9.6 nM). Gint4.T aptamer sodium inhibits PDGFRβ heterodimerization and EGFR transactivation. It can significantly inhibit cell migration and proliferation, induce differentiation and prevent tumor growth in vivo. Gint4.T aptamer sodium specifically inhibits PDGFRβ-mediated tropism of mesenchymal stem cells (MSCs) toward the tumor microenvironment .

HY-149462

KN1022

PDGFR Cardiovascular Disease

KN1022 an inhibitor of phosphorylation of platelet-derived growth factor receptor (PDGFR) with IC₅₀ of 0.24 μM .

KN1022	PDGFR	Cardiovascular Disease
KN1022 an inhibitor of phosphorylation of platelet-derived growth factor receptor (PDGFR) with IC₅₀ of 0.24 μM .

HY-10873S

N-Desethyl Sunitinib-d5	Isotope-Labeled Compounds Drug Metabolite	Cancer
N-Desethyl Sunitinib-d₅ is the deuterium labeled N-Desethyl Sunitinib. N-Desethyl Sunitinib (SU-12662) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor with Ki values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively[1].

HY-108627

DMPQ dihydrochloride

PDGFR Others

DMPQ dihydrochloride is a potent and selective inhibitor of human platelet-derived growth factor receptor β (PDGFRβ) with an IC₅₀ of 80 nM .

DMPQ dihydrochloride	PDGFR	Others
DMPQ dihydrochloride is a potent and selective inhibitor of human *platelet-derived growth factor receptor β (PDGFRβ)* with an IC₅₀ of 80 nM .

HY-10330S

Toceranib-d8	Isotope-Labeled Compounds PDGFR VEGFR c-Kit	Cancer
Toceranib-d₈ is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib (SU11654) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors[1][2].

HY-P0175A

740 Y-P TFA 740YpdgfR TFA; pdgfR 740Y-P TFA	PI3K Autophagy	Cancer
740 Y-P TFA is a potent and cell-permeable PI3K activator. 740 Y-P TFA readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .

HY-50946

Imatinib Mesylate 65+ Cited Publications STI571 Mesylate; CGP-57148B Mesylate	c-Kit Bcr-Abl PDGFR Autophagy	Cancer
Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and *PDGFR* (IC₅₀=100 nM) tyrosine kinases.

HY-16265

JI-101

Ephrin Receptor PDGFR VEGFR Cardiovascular Disease Cancer

JI-101 is an orally available multi-kinase inhibitor of VEGFR2, PDGFRβ and EphB4 with potent anti-cancer activity.

JI-101	Ephrin Receptor PDGFR VEGFR	Cardiovascular Disease Cancer
JI-101 is an orally available multi-kinase inhibitor of VEGFR2, PDGFRβ and EphB4 with potent anti-cancer activity.

HY-G0017

N-Desmethyl imatinib Norimatinib; Imatinib metabolite N-Desmethyl imatinib	Drug Metabolite	Others
N-Desmethyl imatinib (Norimatinib) is a metabolite of Imatinib (HY-15463). Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR .

HY-G0017A

N-Desmethyl imatinib mesylate Norimatinib mesylate; Imatinib metabolite N-Desmethyl imatinib mesylate	Drug Metabolite	Others
N-Desmethyl imatinib mesylate (Norimatinib mesylate) is a metabolite of Imatinib (HY-15463). Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR .

HY-119757A

Tyrphostin AG1433 hydrochloride SU1433 hydrochloride; AG1433 hydrochloride	PDGFR	Inflammation/Immunology
Tyrphostin AG 1433 is a specific and potent inhibitor of *PDGFR-β* and of KDR/Flk-1. Tyrphostin AG 1433 acts as an angiogenesis inhibitor .

HY-10407

SU 5402 5+ Cited Publications	VEGFR FGFR PDGFR	Cancer
SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGFRβ, respectively.

HY-18622

PP58

Src FGFR PDGFR Cancer

PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits PDGFR, FGFR and Src family activities with nanomolar IC₅₀ values.

PP58	Src FGFR PDGFR	Cancer
PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits *PDGFR, FGFR* and Src family activities with nanomolar IC₅₀ values.

HY-W011266

JNJ-10198409 1 Publications Verification	PDGFR	Cancer
JNJ-10198409 is a relatively selective, orally active, and ATP competitive *PDGF-RTK* (platelet-derived growth factor receptor tyrosine kinase) inhibitor (IC₅₀=2 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent. JNJ-10198409 has good activity against *PDGFR-β* kinase (IC₅₀=4.2 nM) and *PDGFR-α* kinase (IC₅₀=45 nM) .

HY-107417

Hypothemycin	VEGFR MEK FLT3 PDGFR ERK	Cancer
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2, respectively .

HY-50905S

Dovitinib-d8	FLT3 c-Kit FGFR VEGFR PDGFR c-Fms	Cancer
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively[1][2].

HY-50751G

Linifanib ABT-869; AL-39324	VEGFR PDGFR	Cancer
Linifanib (ABT-869) (GMP) is Linifanib (HY-50751) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Linifanib is a potent and orally active multi-target inhibitor of VEGFR and *PDGFR* family with IC₅₀s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (GMP) promotes the generation and reprogramming of iPSCs from somatic cells .

HY-10501

SU14813 1 Publications Verification	PDGFR VEGFR c-Kit	Cancer
SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC₅₀s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.

HY-10372

PP121 2 Publications Verification	mTOR PDGFR VEGFR Src Apoptosis	Cancer
PP121 is a multi-targeted kinase inhibitor with IC₅₀s of 10, 60, 12, 14, 2 nM for mTOR, DNK-PK, VEGFR2, Src, *PDGFR*, respectively.

HY-10501A

SU14813 maleate 1 Publications Verification	PDGFR VEGFR c-Kit	Cancer
SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC₅₀s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.

HY-100349

SU4312
SU4312 is the racemate of (Z)-SU4312 and (E)-SU4312. (Z)-SU4312 inhibits PDGFR and FLK-1 with IC₅₀s of 19.4 and 0.8 μM, respectively. (E)-SU4312 inhibits PDGFR, FLK-1, EGFR, HER-2, and IGF-1R with IC₅₀s of 24.2, 5.2, 18.5, 16.9 and 10.0 μM, respectively .

HY-13263

CHIR-124 2 Publications Verification	Checkpoint Kinase (Chk) FLT3 PDGFR Apoptosis	Cancer
CHIR-124 is a potent and selective Chk1 inhibitor with IC₅₀ of 0.3 nM, and also potently targets *PDGFR* and FLT3 with IC₅₀s of 6.6 nM and 5.8 nM.

HY-100315

Tyrosine kinase-IN-1	VEGFR PDGFR FGFR	Cardiovascular Disease
Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 4, 20, 4, 2 nM for KDR, Flt-1, FGFR1 and PDGFRα, respectively.

HY-50905

Dovitinib 5+ Cited Publications CHIR-258; TKI258	FLT3 c-Kit FGFR VEGFR PDGFR c-Fms	Cancer
Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC₅₀s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity .

HY-50751

Linifanib 4 Publications Verification ABT-869; AL-39324	PDGFR VEGFR FLT3 c-Fms c-Kit Autophagy Apoptosis	Cancer
Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and *PDGFR* family with IC₅₀s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib is a specific miR-10b inhibitor that blocks miR-10b biogenesis .

HY-10321

PD173074 5+ Cited Publications	FGFR VEGFR Apoptosis	Cancer
PD173074 is a potent FGFR1 inhibitor with an IC₅₀ of 25 nM and also inhibits VEGFR2 with an IC₅₀ of 100-200 nM, showing 1000-fold selectivity for FGFR1 over PDGFR and c-Src.

HY-10981

Lenvatinib 35+ Cited Publications E7080	VEGFR FGFR PDGFR c-Kit RET	Cancer
Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, *PDGFR, KIT, and RET*, shows potent antitumor activities .

Cat. No.	Product Name

HY-L016

Protein Tyrosine Kinase Compound Library

1045 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1045 compounds that act as a useful tool for PTKs-related drug screening and disease research.

HY-L088

1960 compounds

Angiogenesis is the physiological process through which new blood vessels are formed from pre-existing vessels. It occurs in various physiological processes e.g. embryonic development, menstrual cycle, exercise and wound healing etc. Angiogenesis is regulated by both endogenous activators and inhibitors. Some key activators of angiogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, TGF-β, etc. whereas angiogenesis inhibitors are angiostatin, endostatin, interferon, platelet factor 4, etc. The loss of balance between these opposing signals leads to life threatening diseases like cancer, cardiovascular and ischemic diseases etc. which are thus controlled by exogenous angiogenesis activators (for cardiovascular/ischemic disorders) and inhibitors (for cancer).

MCE offers a unique collection of 1960 compounds with validated angiogenesis targets modulating properties. MCE angiogenesis-related compound library is an effective tool for angiogenesis research and discovery of angiogenesis-related drugs.

Cat. No.	Product Name	Type

HY-50751G

Linifanib (GMP)

ABT-869 (GMP); AL-39324 (GMP)

Fluorescent Dye

Linifanib (ABT-869) (GMP) is Linifanib (HY-50751) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Linifanib is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC₅₀s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (GMP) promotes the generation and reprogramming of iPSCs from somatic cells .

HY-10407G

SU 5402 (GMP)	Fluorescent Dye
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGFRβ, respectively .

Cat. No.	Product Name	Type

HY-50751G

Linifanib (GMP)

ABT-869 (GMP); AL-39324 (GMP)

Biochemical Assay Reagents

Linifanib (ABT-869) (GMP) is Linifanib (HY-50751) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Linifanib is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC₅₀s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (GMP) promotes the generation and reprogramming of iPSCs from somatic cells .

HY-10407G

SU 5402 (GMP)	Biochemical Assay Reagents
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGFRβ, respectively .

Cat. No.	Product Name	Target	Research Area

HY-P0175

740 Y-P 125+ Cited Publications 740YpdgfR; pdgfR 740Y-P	PI3K Autophagy	Cancer
740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .

HY-P0175A

740 Y-P TFA 740YpdgfR TFA; pdgfR 740Y-P TFA	PI3K Autophagy	Cancer
740 Y-P TFA is a potent and cell-permeable PI3K activator. 740 Y-P TFA readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .

Cat. No.	Product Name	Target	Research Area

HY-P99223

Tovetumab MEDI-575	PDGFR	Cancer
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) .

HY-P9922

Olaratumab IMC-3G3; LY3012207	PDGFR	Cancer
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-107417

Hypothemycin	Structural Classification Monophenols Microorganisms Antifungal Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Phenols Disease Research Disease Research Fields Cancer	VEGFR MEK FLT3 PDGFR ERK
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2, respectively .

HY-N0366

Sennoside B 1 Publications Verification	Quinones Structural Classification Classification of Application Fields Leguminosae Anthraquinones Plants Cassia angustifolia Disease Research Fields Cancer	PDGFR
Sennoside B is an anthraquinone glycoside, found in large quantities in leaves and pods of Senna (Cassia angustifolia) . Sennoside B can inhibit PDGF-stimulated cell proliferation by binding to PDGF-BB and its receptor and by down-regulating the PDGFR-beta signaling pathway .

HY-N0366R

Sennoside B (Standard)	Quinones Structural Classification Classification of Application Fields Leguminosae Source classification Plants Cassia angustifolia Disease Research Fields Cancer	PDGFR
Sennoside B (Standard) is the analytical standard of Sennoside B. This product is intended for research and analytical applications. Sennoside B is an anthraquinone glycoside, found in large quantities in leaves and pods of Senna (Cassia angustifolia) . Sennoside B can inhibit PDGF-stimulated cell proliferation by binding to PDGF-BB and its receptor and by down-regulating the PDGFR-beta signaling pathway .

Species:	Human (10) Rhesus Macaque (2) Mouse (2) Rat (4) Cynomolgus (1) Canine (1)
Tag:	His (14) Avi (4) Fc (6)
Source:	HEK293 (19) Sf9 insect cells (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P72494

	PDGF R beta Protein, Human (HEK293, His) Platelet-derived growth factor receptor beta; pdgf-R-beta; pdgfR-1; CD140b; pdgfRB	Human	HEK293
	TRF1 protein is a telomere-binding protein that plays a crucial role in telomere maintenance and chromosome stability. It is involved in regulating telomere length and preventing DNA damage. PDGF R beta Protein, Human (HEK293, His) is the recombinant human-derived PDGF R beta protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PDGF R beta Protein, Human (HEK293, His) is 499 a.a., with molecular weight of 85-130 kDa.

HY-P72495

	PDGF R alpha Protein, Human (HEK293, His) Platelet-derived growth factor receptor alpha; pdgf-R-alpha; pdgfR-2; CD140a; pdgfRA	Human	HEK293
	PDGF R α is a tyrosine protein kinase and an important cell surface receptor for PDGFA, PDGFB and PDGFC, affecting embryonic development, cell proliferation, survival and chemotaxis. Its effects on cell behavior vary, promoting or inhibiting proliferation and migration depending on environmental cues. PDGF R alpha Protein, Human (HEK293, His) is the recombinant human-derived PDGF R alpha protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PDGF R alpha Protein, Human (HEK293, His) is 501 a.a., with molecular weight of ~93 kDa.

HY-P700810

	PDGF R beta Protein, Canine (HEK293, His) JTK12; pdgf R beta; pdgfR; pdgfR1; pdgfRB; CD140B; pdgfR-2; pdgfR-β; pdgf R β	Canine	HEK293
	PDGF R beta Protein is a tyrosine protein kinase that plays an important role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. PDGF R beta Protein, Canine (HEK293, His) is the recombinant canine-derived PDGF R beta protein, expressed by HEK293 , with C-His labeled tag. The total length of PDGF R beta Protein, Canine (HEK293, His) is 501 a.a., with molecular weight of 70-100 kDa.

HY-P78194

	PDGF R beta Protein, Human (Biotinylated, HEK293, His-Avi) JTK12; pdgf R beta; pdgfR; pdgfR1; pdgfRB; CD140B; pdgfR-2; pdgfR-β; pdgf R β	Human	HEK293
	PDGF Rβ protein is integral in embryonic development and regulates cell proliferation, survival, differentiation, chemotaxis, migration, and vascular development. It crucially recruits pericytes and smooth muscle cells to the endothelium, promoting vascular smooth muscle cell migration and neointimal formation at the site of injury. PDGF R beta Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived PDGF R beta protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of PDGF R beta Protein, Human (Biotinylated, HEK293, His-Avi) is 498 a.a., with molecular weight of 78-115 kDa.

HY-P78506

	PDGF R alpha Protein, Human (HEK293, His-Avi) pdgfRA; CD140A; pdgfR2; RHEpdgfRA; MGC74795; pdgfR-2	Human	HEK293
	PDGF R α is a tyrosine protein kinase and an important cell surface receptor for PDGFA, PDGFB and PDGFC, affecting embryonic development, cell proliferation, survival and chemotaxis. Its effects on cell behavior vary, promoting or inhibiting proliferation and migration depending on environmental cues. PDGF R alpha Protein, Human (HEK293, His-Avi) is the recombinant human-derived PDGF R alpha protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of PDGF R alpha Protein, Human (HEK293, His-Avi) is 501 a.a., with molecular weight of 70-83 kDa.

HY-P72496

	PDGF R alpha Protein, Mouse (HEK293, His) Platelet-derived growth factor receptor alpha; pdgf-R-alpha; pdgfR-2; CD140a; pdgfRA	Mouse	HEK293
	PDGF R α is a tyrosine-protein kinase receptor with critical effects on embryonic development, cell proliferation, survival, and chemotaxis. Its effects on cell behavior vary depending on the environment and is critical for differentiation of bone marrow mesenchymal stem cells, normal skeletal development, embryonic skull closure, and gastrointestinal mucosal formation. PDGF R alpha Protein, Mouse (HEK293, His) is the recombinant mouse-derived PDGF R alpha protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PDGF R alpha Protein, Mouse (HEK293, His) is 500 a.a., with molecular weight of 80-120 kDa.

HY-P73360

	PDGF R beta Protein, Rat (HEK293, His) Platelet-derived growth factor receptor beta; pdgf-R-beta; pdgfR-1; CD140b; pdgfRB	Rat	HEK293
	PDGF R beta Protein, a receptor tyrosine kinase, binds ligands PDGFA, PDGFB, and PDGFD, forming homodimers or heterodimers. Ligand binding activates diverse signaling cascades in PDGF R beta, with responses contingent on the specific ligand. The modulation of responses involves heterodimer formation with another receptor, PDGFRB. PDGF R beta Protein, Rat (HEK293, His) is the recombinant rat-derived PDGF R beta protein, expressed by HEK293 , with C-His labeled tag. The total length of PDGF R beta Protein, Rat (HEK293, His) is 500 a.a., with molecular weight of 80-110 kDa.

HY-P74644

	PDGF R beta Protein, Rat (HEK293, Fc) Platelet-derived growth factor receptor beta; pdgf-R-beta; pdgfR-1; CD140b; pdgfRB	Rat	HEK293
	PDGF R beta Protein, a receptor tyrosine kinase, binds ligands PDGFA, PDGFB, and PDGFD, forming homodimers or heterodimers. Ligand binding activates diverse signaling cascades in PDGF R beta, with responses contingent on the specific ligand. The modulation of responses involves heterodimer formation with another receptor, PDGFRB. PDGF R beta Protein, Rat (HEK293, Fc) is the recombinant rat-derived PDGF R beta protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PDGF R beta Protein, Rat (HEK293, Fc) is 499 a.a., with molecular weight of ~117 kDa.

HY-P77124

	PDGF R beta Protein, Human (HEK293, Fc) Platelet-derived growth factor receptor beta; pdgf-R-beta; pdgfR-1; CD140b; pdgfRB	Human	HEK293
	TRF1 protein is a telomere-binding protein that plays a crucial role in telomere maintenance and chromosome stability. It is involved in regulating telomere length and preventing DNA damage. PDGF R beta Protein, Human (HEK293, Fc) is the recombinant human-derived PDGF R beta protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PDGF R beta Protein, Human (HEK293, Fc) is 498 a.a., with molecular weight of ~82.8 KDa.

HY-P77127

	PDGF R beta Protein, Human (Biotinylated, HEK293, His) Platelet-derived growth factor receptor beta; pdgf-R-beta; pdgfR-1; CD140b; pdgfRB	Human	HEK293
	TRF1 protein is a telomere-binding protein that plays a crucial role in telomere maintenance and chromosome stability. It is involved in regulating telomere length and preventing DNA damage. PDGF R beta Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived PDGF R beta protein, expressed by HEK293 , with C-His labeled tag. The total length of PDGF R beta Protein, Human (Biotinylated, HEK293, His) is 499 a.a., with molecular weight of ~57.6 KDa.

HY-P77128

	PDGF R beta Protein, Rhesus Macaque (HEK293, Fc) Platelet-derived growth factor receptor beta; pdgf-R-beta; pdgfR-1; CD140b; pdgfRB	Rhesus Macaque	HEK293
	PDGF R beta, a tyrosine-protein kinase receptor, crucially regulates embryonic development, overseeing cell processes like proliferation, survival, differentiation, chemotaxis, and migration. Especially vital in blood vessel development, it facilitates pericyte and smooth muscle cell proliferation, migration, and recruitment to endothelial cells, playing a significant role in blood vessel formation and maintenance. PDGF R beta Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived PDGF R beta protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PDGF R beta Protein, Rhesus Macaque (HEK293, Fc) is 530 a.a., with molecular weight of ~83.3 KDa.

HY-P77129

	PDGF R beta Protein, Rhesus Macaque (HEK293, His) Platelet-derived growth factor receptor beta; pdgf-R-beta; pdgfR-1; CD140b; pdgfRB	Rhesus Macaque	HEK293
	PDGF R beta, a tyrosine-protein kinase receptor, crucially regulates embryonic development, overseeing cell processes like proliferation, survival, differentiation, chemotaxis, and migration. Especially vital in blood vessel development, it facilitates pericyte and smooth muscle cell proliferation, migration, and recruitment to endothelial cells, playing a significant role in blood vessel formation and maintenance. PDGF R beta Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived PDGF R beta protein, expressed by HEK293 , with C-His labeled tag. The total length of PDGF R beta Protein, Rhesus Macaque (HEK293, His) is 498 a.a., with molecular weight of ~80-96 KDa.

HY-P78193

	PDGF R alpha Protein, Human (Biotinylated, HEK293, His-Avi) pdgfRA; CD140A; pdgfR2; RHEpdgfRA; MGC74795; pdgfR-2	Human	HEK293
	PDGF R α is a tyrosine protein kinase and an important cell surface receptor for PDGFA, PDGFB and PDGFC, affecting embryonic development, cell proliferation, survival and chemotaxis. Its effects on cell behavior vary, promoting or inhibiting proliferation and migration depending on environmental cues. PDGF R alpha Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived PDGF R alpha protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of PDGF R alpha Protein, Human (Biotinylated, HEK293, His-Avi) is 501 a.a., with molecular weight of 70-83 kDa.

HY-P77123

	PDGF R beta Protein, Human (HEK293, C-His-Avi) Platelet-derived growth factor receptor beta; pdgf-R-beta; pdgfR-1; CD140b; pdgfRB	Human	HEK293
	PDGF Rβ protein is integral in embryonic development and regulates cell proliferation, survival, differentiation, chemotaxis, migration, and vascular development. It crucially recruits pericytes and smooth muscle cells to the endothelium, promoting vascular smooth muscle cell migration and neointimal formation at the site of injury. PDGF R beta Protein, Human (HEK293, C-His-Avi) is the recombinant human-derived PDGF R beta protein, expressed by HEK293 , with C-His, C-Avi labeled tag. The total length of PDGF R beta Protein, Human (HEK293, C-His-Avi) is 498 a.a., with molecular weight of 78-115 kDa.

HY-P73356

	PDGF R alpha Protein, Human (HEK293, Fc) Platelet-derived growth factor receptor alpha; pdgfR-alpha; pdgfR-2; CD140a; pdgfRA	Human	HEK293
	PDGF R α is a tyrosine protein kinase and an important cell surface receptor for PDGFA, PDGFB and PDGFC, affecting embryonic development, cell proliferation, survival and chemotaxis. Its effects on cell behavior vary, promoting or inhibiting proliferation and migration depending on environmental cues. PDGF R alpha Protein, Human (HEK293, Fc) is the recombinant human-derived PDGF R alpha protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PDGF R alpha Protein, Human (HEK293, Fc) is 524 a.a., with molecular weight of 120-130 kDa.

HY-P73721

	PDGF R alpha Protein, Rat (HEK293, His) Platelet-derived growth factor receptor alpha; pdgfR-alpha; pdgfR-2; CD140a; pdgfRA	Rat	HEK293
	PDGF R alpha protein is a tyrosine protein kinase receptor for PDGFA, PDGFB, and PDGFC that coordinates embryonic development, cell proliferation, survival, and chemotaxis. Their functions vary, promoting or inhibiting cell proliferation and migration depending on the situation. PDGF R alpha Protein, Rat (HEK293, His) is the recombinant rat-derived PDGF R alpha protein, expressed by HEK293 , with C-His labeled tag. The total length of PDGF R alpha Protein, Rat (HEK293, His) is 500 a.a., with molecular weight of 70-110 kDa.

HY-P73722

	PDGF R alpha Protein, Rat (HEK293, Fc) Platelet-derived growth factor receptor alpha; pdgfR-alpha; pdgfR-2; CD140a; pdgfRA	Rat	HEK293
	PDGF R alpha protein is a tyrosine protein kinase receptor for PDGFA, PDGFB, and PDGFC that coordinates embryonic development, cell proliferation, survival, and chemotaxis. Their functions vary, promoting or inhibiting cell proliferation and migration depending on the situation. PDGF R alpha Protein, Rat (HEK293, Fc) is the recombinant rat-derived PDGF R alpha protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PDGF R alpha Protein, Rat (HEK293, Fc) is 523 a.a., with molecular weight of 112-120 kDa.

HY-P74645

	PDGF R alpha Protein, Mouse (HEK293, Fc) Platelet-derived growth factor receptor alpha; pdgfR-alpha; pdgfR-2; CD140a; pdgfRA	Mouse	HEK293
	PDGF R α is a tyrosine-protein kinase receptor with critical effects on embryonic development, cell proliferation, survival, and chemotaxis. Its effects on cell behavior vary depending on the environment and is critical for differentiation of bone marrow mesenchymal stem cells, normal skeletal development, embryonic skull closure, and gastrointestinal mucosal formation. PDGF R alpha Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived PDGF R alpha protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PDGF R alpha Protein, Mouse (HEK293, Fc) is 528 a.a., with molecular weight of ~83.15 kDa.

HY-P700809

	PDGF R alpha Protein, Cynomolgus (501a.a, HEK293, His) pdgfRA; CD140A; pdgfR2; RHEpdgfRA; MGC74795; pdgfR-2	Cynomolgus	HEK293
	PDGF R alpha Protein, a tyrosine-protein kinase receptor, crucially influences embryonic development, regulating cell proliferation, survival, and chemotaxis. Its effects on cell behavior vary contextually, either promoting or inhibiting proliferation and migration. Additionally, it plays a significant role in differentiating bone marrow-derived mesenchymal stem cells and is essential for normal skeletal development. PDGF R alpha Protein, Cynomolgus (501a.a, HEK293, His) is the recombinant cynomolgus-derived PDGF R alpha protein, expressed by HEK293 , with C-His labeled tag. The total length of PDGF R alpha Protein, Cynomolgus (501a.a, HEK293, His) is 501 a.a., with molecular weight of 70-85 kDa.

HY-P702756

	PDGF R beta Protein, Human (Biotinylated, sf9, His) pdgfRB; platelet-derived growth factor receptor, beta polypeptide; pdgfR; platelet-derived growth factor receptor beta; CD140b; JTK12; pdgfR1; pdgfR-beta; pdgf-R-beta; CD140 antigen-like family member B; platelet-derived growth factor receptor 1; beta-type platelet-derived growth factor receptor; CD140B; pdgfR-1	Human	Sf9 insect cells

Cat. No.	Product Name	Chemical Structure

HY-10873S

N-Desethyl Sunitinib-d5
N-Desethyl Sunitinib-d₅ is the deuterium labeled N-Desethyl Sunitinib. N-Desethyl Sunitinib (SU-12662) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor with Ki values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively[1].

HY-15463S

Imatinib-d8 1 Publications Verification
Imatinib-d₈ is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2].

HY-15463S1

Imatinib-d4
Imatinib-d₄ is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2].

HY-10330S

Toceranib-d8
Toceranib-d₈ is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib (SU11654) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors[1][2].

HY-50905S

Dovitinib-d8
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively[1][2].

HY-10981S1

Lenvatinib-d5
Lenvatinib-d₅ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].

HY-10981S

Lenvatinib-d4
Lenvatinib-d₄ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].

HY-13904S

Flumatinib-d3
Flumatinib-d₃ is deuterium labeled Flumatinib. Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively[1].

HY-G0017S1

N-Desmethyl imatinib-d4
N-Desmethyl imatinib-d₄ is the deuterium-labeled N-Desmethyl imatinib (HY-G0017). N-Desmethyl imatinib-d₄ (Norimatinib) is a metabolite of Imatinib (HY-15463). Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR .

HY-10208S

Pazopanib-d6
Pazopanib-d₆ is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-10065S

Axitinib-13C,d3
Axitinib- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively.

HY-10255AS1

Sunitinib-d4
Sunitinib-d₄ is the deuterium labeled Sunitinib. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].

HY-10065S1

Axitinib-d3
Axitinib-d₃ (AG-013736-d3) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively[1].

HY-W758126

(R)-Brivanib alaninate-d4
(R)-Brivanib alaninate-d₄ is the deuterium-labeled Brivanib (alaninate) (HY-10336). Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC₅₀ of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ .

HY-10331S1

Regorafenib-13C,d3
Regorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Regorafenib. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.

HY-10208S1

Pazopanib-13C,d3
Pazopanib- ¹³C,d₃ is the deuterium and ¹³C labeled Pazopanib[1]. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-12009S

Pazopanib-13C,d3 hydrochloride
Pazopanib- ¹³C,d₃ (hydrochloride) is the deuterium and ¹³C labeled Pazopanib hydrochloride[1]. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-50904S

Nintedanib-d3
Nintedanib-d₃ is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-50904S2

Nintedanib-d8
Nintedanib-d₈ is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-15463S2

Imatinib-d3 hydrochloride

Imatinib-d₃ (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.

HY-50904S1

Nintedanib-13C,d3
Nintedanib- ¹³C,d₃ is the ¹³C- and deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-I0678S1

Regorafénib N-oxyde (M2)-13C,d3
Regorafénib N-oxyde (M2)- ¹³C,d₃ is the ¹³C- and deuterium labeled Regorafénib N-oxyde (M2). Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

HY-I0678S

Regorafénib N-oxyde-d3 (M2)
Regorafénib N-oxyde-d₃(M2) is the deuterium labeled Regorafénib N-oxyde M2[1]. Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively[2].

HY-10201S2

Sorafenib-13C,d3

Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

HY-13342AS

Apatinib-d8 free base

Apatinib-d₈ (free base) is the deuterium labeled Apatinib free base[1]. Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC50=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the research of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC50s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ[2][3][4].

Cat. No.	Product Name	Application	Reactivity

HY-P82180

PDGFR beta Antibody (YA1925) pdgfRB; pdgfR; pdgfR1; Platelet-derived growth factor receptor beta; pdgf-R-beta; pdgfR-beta; Beta platelet-derived growth factor receptor; Beta-type platelet-derived growth factor receptor; CD140 antigen-like family member B; Platelet-deri	WB, IP	Human, Mouse, Rat

HY-P83317

*Phospho-PDGFR* beta (Tyr740) Antibody (YA3062)** pdgfRB; pdgfR; pdgfR1; Platelet-derived growth factor receptor beta; pdgf-R-beta; pdgfR-beta; Beta platelet-derived growth factor receptor; Beta-type platelet-derived growth factor receptor; CD140 antigen-like family member B; Platelet-deri	WB, ICC/IF	Mouse, Rat

HY-P80510

PDGFR alpha Antibody	WB, ICC, IHC-P, FC	Human, Mouse
PDGFR alpha Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 123 kDa, targeting to PDGFR alpha. It can be used for WB,ICC,IHC-P,FC assays with tag free, in the background of Human, Mouse.

HY-P80278

*Phospho-PDGFR* beta (Y740) Antibody**	WB, ICC/IF	Human, Rat
Phospho-PDGFR beta (Y740) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 124 kDa, targeting to Phospho-PDGFR beta (Y740). It can be used for WB,ICC/IF assays with tag free, in the background of Human, Rat.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

pdgf-r-alpha-protein-mouse-528a-a-hek293-his

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products